Aceragen Acquires Potential Oral Antibiotic for CF Pulmonary Flares

Aceragen Acquires Potential Oral Antibiotic for CF Pulmonary Flares

310917

Aceragen Acquires Potential Oral Antibiotic for CF Pulmonary Flares

Aceragen reached an agreement to acquire Arrevus, including its late-stage clinical program of ARV-1801 — now called ACG-721 — an experimental oral therapy for pulmonary exacerbations in cystic fibrosis (CF) patients. Aceragen is planning to launch a Phase 2/3 clinical trial in the second half of 2022 to evaluate ACG-721’s safety and effectiveness in CF patients with pulmonary exacerbations. Arrevus’ portfolio also includes preclinical programs with potential application to treatment-resistant bacterial infections and cancer. “The acquisition…

You must be logged in to read/download the full post.